Inhalation drug delivery devices: Technology update

Medical Devices: Evidence and Research

Volumn 8, Issue , 2015, Pages 131-139

  Ibrahim, Mariam ^a   Verma, Rahul ^a   Garcia Contreras, Lucila ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Asthma; Dry powder inhaler; Metered dose inhaler; Nebulizers; Pulmonary delivery

Indexed keywords

AEROSOLS; TARGETED DRUG DELIVERY;

ASTHMA; DRY POWDER INHALER; METERED-DOSE INHALERS; NEBULIZERS; PULMONARY DELIVERY;

CONTROLLED DRUG DELIVERY;

AEROSOL; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER INHALER; EQUIPMENT DESIGN; HUMAN; INHALATION SPACER; INHALATIONAL DRUG ADMINISTRATION; METERED DOSE INHALER; NEBULIZER; PHYSICAL CHEMISTRY; REVIEW; SOFT MIST INHALER; VAPORIZATION; VAPORIZER;

EID: 84922892006     PISSN: None     EISSN: 11791470     Source Type: Journal    
DOI: 10.2147/MDER.S48888     Document Type: Review

References (80)

1. Anderson PJ. History of aerosol therapy: liquid nebulization to MDIs to DPIs. Respir Care. 2005;50(9):1139–1150.
2. Sanders M. Inhalation therapy: an historical review. Prim Care Respir J. 2007;16(2):71–81.
3. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):588–599.
4. Crompton G. A brief history of inhaled asthma therapy over the last fifty years. Prim Care Respir J. 2006;15(6):326–331.
5. Hess DR. Aerosol delivery devices in the treatment of asthma. Respir Care. 2008;53(6):699–723; discussion 723–725.
6. Chow AH, Tong HH, Chattopadhyay P, Shekunov B Y. Particle engineering for pulmonary drug delivery. Pharm Res. 2007;24(3):411–437.
7. Ibrahim M, Garcia-Contreras L. Mechanisms of absorption and elimination of drugs administered by inhalation. Ther Deliv. 2013;4(8): 1027–1045.
8. Verma RK, Ibrahim M, Lucila G-C. Lung anatomy and physiology and their implications for pulmonary drug delivery. In: Nokhodchi A, editor. Pulmonary Drug Delivery: Advances and Challenges. Oxford, UK: John Wiley Publishers; 2014. inpress
9. Heyder J. Particle transport onto human airway surfaces. Eur J Respir Dis Suppl. 1982;119:29–50.
10. Hinds WC, Liu WC, Froines JR. Particle bounce in a personal cascade impactor: a field evaluation. Am Ind Hyg Assoc J. 1985;46(9): 517–523.
11. Zanen P, Go LT, Lammers J W. The efficacy of a low-dose, monodisperse parasympathicolytic aerosol compared with a standard aerosol from a metered-dose inhaler. Eur J Clin Pharmacol. 1998;54(1):27–30.
12. Farr SJ, Rowe AM, Rubsamen R, Taylor G. Aerosol deposition in the human lung following administration from a microprocessor controlled pressurised metered dose inhaler. Thorax. 1995;50(6):639–644.
13. Ari A, Restrepo RD. American Association for Respiratory C. Aerosol delivery device selection for spontaneously breathing patients: 2012. Respir Care. 2012;57(4):613–626.
14. Newman S P. Aerosol deposition considerations in inhalation therapy. Chest. 1985;88(Suppl 2):152S–160S.
15. Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37(6):1308–1331.
16. Zhou QT, Tang P, Leung SS, Chan JG, Chan HK. Emerging inhalation aerosol devices and strategies: where are we headed? Adv Drug Deliv Rev. 2014;75C:3–17.
17. Darquenne C. Aerosol deposition in health and disease. J Aerosol Med Pulm Drug Deliv. 2012;25(3):140–147.
18. Dunbar CA, Hickey AJ, Holzner P. Dispersion and characterization of pharmaceutical dry powder aerosols. KONA Powder Part J. 1998;16: 7–45.
19. Hess DR. Nebulizers: principles and performance. Respir Care. 2000;45(6):609–622.
20. Watts AB, McConville JT, Williams RO 3rd. Current therapies and technological advances in aqueous aerosol drug delivery. Drug Dev Ind Pharm. 2008;34(9):913–922.
21. Rubin BK, Williams RW. Emerging aerosol drug delivery strategies: from bench to clinic. Adv Drug Deliv Rev. 2014;75C:141–148.
22. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet. 2011;377(9770):1032–1045.
23. Davies LA, Nunez-Alonso GA, McLachlan G, Hyde SC, Gill DR. Aerosol delivery of DNA/liposomes to the lung for cystic fibrosis gene therapy. Hum Gene Ther Clin Dev. 2014;25(2):97–107.
24. Pitance L, Reychler G, Leal T, et al. Aerosol delivery to the lung is more efficient using an extension with a standard jet nebulizer than an open-vent jet nebulizer. J Aerosol Med Pulm Drug Deliv. 2013;26(4):208–214.
25. Skaria S, Smaldone GC. Omron NE U22: comparison between vibrating mesh and jet nebulizer. J Aerosol Med Pulm Drug Deliv. 2010;23(3):173–180.
26. Fischer A, Stegemann J, Scheuch G, Siekmeier R. Novel devices for individualized controlled inhalation can optimize aerosol therapy in effcacy, patient care and power of clinical trials. Eur J Med Res. 2009;14(Suppl 4):71–77.
27. Nikander K, Prince I, Coughlin S, Warren S, Taylor G. Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of (99m)Tc-DTPA. J Aerosol Med Pulm Drug Deliv. 2010;23(Suppl 1):S37–S43.
28. Sabato K, Ward P, Hawk W, Gildengorin V, Asselin JM. Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department. Respir Care. 2011;56(6):761–770.
29. Luisetti M, Kroneberg P, Suzuki T, et al. Physical properties, lung deposition modeling, and bioactivity of recombinant GM-CSF aerosolised with a highly efficient nebulizer. Pulm Pharmacol Ther. 2011;24(1):123–127.
30. CompAIR NE-C801. OMRON Healthcare Europe BV; August 19, 2014. Available from: http://www.omron-healthcare.com/eu/en/our-products/respiratory-therapy/compair-ne-c801.
31. Geller DE, Kesser KC. The I-neb adaptive aerosol delivery system enhances delivery of alpha1-antitrypsin with controlled inhalation. J Aerosol Med Pulm Drug Deliv. 2010;23(Suppl 1):S55–S59.
32. Najlah M, Parveen I, Alhnan MA, et al. The effects of suspension particle size on the performance of air-jet, ultrasonic and vibrating-mesh nebulisers. Int J Pharm. 2014;461(1–2):234–241.
33. Govoni M, Poli G, Acerbi D, et al. Pharmacokinetic and tolerability profles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients. Pulm Pharmacol Ther. 2013;26(2):249–255.
34. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J. 2002;20(3):658–664.
35. Vaswani SK, Creticos PS. Metered dose inhaler: past, present, and future. Ann Allergy Asthma Immunol. 1998;80(1):11–19; quiz 19–20.
36. Smyth HD. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv Drug Deliv Rev. 2003;55(7):807–828.
37. Cummings RH. Pressurized metered dose inhalers: chlorofluorocarbon to hydrofluoroalkane transition-valve performance. J Allergy Clin Immunol. 1999;104(6):S230–S236.
38. Stein S W, Sheth P, Hodson PD, Myrdal PB. Advances in metered dose inhaler technology: hardware development. AAPS PharmSciTech. 2014;15(2):326–338.
39. Smyth HD. Propellant-driven metered-dose inhalers for pulmonary drug delivery. Expert Opin Drug Deliv. 2005;2(1):53–74.
40. Newman S P. Principles of metered-dose inhaler design. Respir Care. 2005;50(9):1177–1190.
41. Li HY, Seville PC. Novel pMDI formulations for pulmonary delivery of proteins. Int J Pharm. 2010;385(1–2):73–78.
42. Bains BK, Birchall JC, Toon R, Taylor G. In vitro reporter gene transfection via plasmid DNA delivered by metered dose inhaler. J Pharm Sci. 2010;99(7):3089–3099.
43. Hoe S, Boraey MA, Ivey J W, Finlay WH, Vehring R. Manufacturing and device options for the delivery of biotherapeutics. J Aerosol Med Pulm Drug Deliv. 2014;27(5):315–328.
44. Li YNL, Liu M, Webb K. Addressing China’s growing need for inhaled drugs: development strategies for marketing, distribution, and regulation. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr S, Young PM, editors. Respiratory Drug Delivery. River Grove, IL: Davis Healthcare International Publishing, LLC; 2014:131–142.
45. Crompton GK. Breath-activated aerosol. Br Med J. 1971;2(5762): 652–653.
46. Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. EDICI. Respir Med. 2000;94(5):496–500.
47. Kelkar MS, Dalby RN. Effervescent aerosols: a novel formulation technology for pressurized metered dose inhalers. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr S, Young PM, editors. Respiratory Drug Delivery. River Grove, IL: Davis Healthcare International Publishing, LCC; 2014:669–672.
48. Steckel H, Muller B W. Metered-dose inhaler add-on devices: an in vitro evaluation of the BronchoAir inhaler and several spacer devices. J Aerosol Med. 1998;11(3):133–142.
49. Terzano C, Mannino F. Probability of particle and salbutamol deposition in the respiratory tract: comparison between MDI and Autohaler. Monaldi Arch Chest Dis. 1996;51(3):236–242.
50. Wildhaber JH, Waterer G W, Hall GL, Summers QA. Reducing electrostatic charge on spacer devices and bronchodilator response. Br J Clin Pharmacol. 2000;50(3):277–280.
51. Kunkel G, Magnussen H, Bergmann K, et al. Respimat (a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients. Respiration. 2000;67(3):306–314.
52. Dalby RN, Eicher J, Zierenberg B. Development of Respimat® Soft Mist Inhaler and its clinical utility in respiratory disorders. Med Devices. 2011;4:145–155.
53. Lavorini F. The challenge of delivering therapeutic aerosols to asthma patients. ISRN Allergy. 2013;2013:102418.
54. US Food and Drug Administration. FDA Approves Combivent Respimat (Ipratropium Bromide and Albuterol Sulfate) Inhalation Spray. Washington DC: US Department of Health and Human Services; [updated October 7, 2011/October 2, 2014].
55. Sanchis J, Corrigan C, Levy ML, Viejo JL, Group A. Inhaler devices – from theory to practice. Respir Med. 2013;107(4):495–502.
56. Lippmann M, Yeates DB, Albert RE. Deposition, retention, and clearance of inhaled particles. Br J Ind Med. 1980;37(4):337–362.
57. Chan JG, Duke CC, Ong HX, et al. A novel inhalable form of rifapentine. J Pharm Sci. 2014;103(5):1411–1421.
58. Begat P, Morton DA, Shur J, Kippax P, Staniforth JN, Price R. The role of force control agents in high-dose dry powder inhaler formulations. J Pharm Sci. 2009;98(8):2770–2783.
59. Islam N, cleary MJ. Developing an effcient and reliable dry powder inhaler for pulmonarydrug delivery-a review for multidisciplinary researchers. Medical engineering and physics. 2012;34(4):409–427.
60. Timothy Crowder MD. Science and technology of dry powder inhalers. In: Smyth HDC, Hickey AJ, editors. Controlled Pulmonary Drug Delivery. New York: Springer; 2011;203–222.
61. Bell JH, Hartley PS, Cox JS. Dry powder aerosols. I. A new powder inhalation device. J Pharm Sci. 1971;60(10):1559–1564.
62. Ashurst II, Malton A, Prime D, Sumby B. Latest advances in the development of dry powder inhalers. Pharm Sci Technolo Today. 2000;3(7):246–256.
63. Atkins PJ. Dry powder inhalers: an overview. Respir Care. 2005;50(10): 1304–1312; discussion 1312.
64. Tiddens HA, Geller DE, Challoner P, et al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J Aerosol Med. 2006;19(4):456–465.
65. Dunbar CA, Concessio NM, Hickey AJ. Evaluation of atomizer performance in production of respirable spray-dried particles. Pharm Dev Technol. 1998;3(4):433–441.
66. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6): 600–612.
67. Crowder T, Hickey A, Warden J, inventor. Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages. United States patent US 20040025877 A1. February 12, 2004.
68. Systems MDD. Comparative Performance of the 3MTM Taper Dry Powder Inhaler Device; 2011. Available from: http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?locale=en_WW&lmd=1314027541000&assetId=1273684150144&assetType=MMM_ Image&blobAttribute=ImageFile. Accessed October 2, 2014.
69. Systems MDD. Developing an Efficient Dry Powder Inhaler 3M Conix™ DPI; 2011. Available from: http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1301085878000&locale=en_WW&assetType=MMM_Image&assetId=1273680315945& blobAttribute=ImageFile. Accessed October 2, 2014.
70. Chrystyn H, Niederlaender C. The Genuair(R) inhaler: a novel, multidose dry powder inhaler. Int J Clin Pract. 2012;66(3):309–317.
71. Kanniess F, Scuri M, Vezzoli S, Francisco C, Petruzzelli S. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler®) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: a randomised, double-blind trial. Pulm Pharmacol Ther. 2014.
72. Geena M, Pragati R, Vrinda M, Bhumika A, Jaideep AG. Revolizer®: the next generation novel single dose dry powder inhaler. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr S, Young PM, editors. Respiratory Drug Delivery. River Grove, IL: Davis Healthcare International Publishing, LCC; 2014:401–404.
73. Svedsater H, Dale P, Garrill K, Walker R, Woepse M W. Qualitative assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med. 2013;13:72.
74. OPKO. INSPIROMATIC™. Available from http://investor.opko.com/releasedetail.cfm?ReleaseID=850077. May 22, 2014. Accessed at November 18, 2014.
75. Vectura. Positive Results for Once-Daily Ultibro® Breezhaler® Versus Combination Therapy (Tiotropium Plus Formoterol); 2014 [updated May 21, 2014; cited October 2, 2014]. Available from: http://www.vectura.com/media/press-releases/2014/21-may-2014a.aspx. Accessdate 10.02.2014
76. ManKind Corporation. Patient-Focused Dry Powder Inhalers; Available from: http://www.mannkindcorp.com/Collateral/Documents/English-US/102LR-DeviceTechTeaser-01.19.11.pdf. Accessed October 2, 2014. published at 2011
77. Vectura. Vectura Announces CE Mark for Aspirair® Inhaler; 2007. Available from: http://www.vectura.com/media/press-releases/archive/2007/2007-01-24.aspx. Accessed October 2, 2014.
78. Cipolla DC, Gonda I. Formulation technology to repurpose drugs for inhalation delivery. Drug Discov Today: Ther Strateg. 2011;8(3–4): 123–130.
79. Simis K, Lei M, Lu AT, et al. Nicotine aerosol generation from thermally reversible zinc halide complexes using the Staccato system. Drug Dev Ind Pharm. 2008;34(9):936–942.
80. Teva Pharmaceuticals. Product Monograph Adasuve (Loxapine) Inhalation Powder. [updated October 02, 2014]. Available from: http://adasuve.com/PDF/Adasuve_Formulary_kit_Monograph.pdf. published at May 21, 2014.